Cutia Therapeutics Completes Trial of Adipose Accumulation Drug to Show Safety, Efficacy

Like
Comment
Favorite

Cutia Therapeutics Completes Trial of Adipose Accumulation Drug to Show Safety, Efficacy

MT Newswires Live2024-12-31

Cutia Therapeutics (HKG:2487) has completed the phase II clinical trial of CU-20401 for submental adipose accumulation in China, a Tuesday bourse filing said.

The clinical trial has shown significant and robust efficacy advantages with a favorable safety profile.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

抱歉，当前请求异常(-1)

7x24

All

23:06
LG Energy Solution: to Supply ESS to Poland's Pge of About 16 Gigawatts From 2026
23:04
Mindax - Raised a$7.2 Mln at Issue Price a$0.05 per Share
22:58
Li-S Energy Ltd - Collaboration With Kea Aerospace to Power High Altitude Uavs
22:56
Eurogroup Laminations Spa - Consolidated Revenues for 2024 Amounted to EUR 869.4 Mln
22:56
Eurogroup Laminations Spa - Adjusted Ebitda for 2024 Stood at EUR 116 Mln

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2495631675?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2024-12-31 12:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2495631675","market":"us","top_or_hot":-1,"title":"Cutia Therapeutics Completes Trial of Adipose Accumulation Drug to Show Safety, Efficacy","media":"MT Newswires Live","content":"<html><body><p> Cutia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (HKG:2487) has completed the phase II clinical trial of CU-20401 for submental adipose accumulation in China, a Tuesday bourse filing said.</p><p>The clinical trial has shown significant and robust efficacy advantages with a favorable safety profile.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cutia Therapeutics Completes Trial of Adipose Accumulation Drug to Show Safety, Efficacy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCutia Therapeutics Completes Trial of Adipose Accumulation Drug to Show Safety, Efficacy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-12-31 12:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Cutia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (HKG:2487) has completed the phase II clinical trial of CU-20401 for submental adipose accumulation in China, a Tuesday bourse filing said.</p><p>The clinical trial has shown significant and robust efficacy advantages with a favorable safety profile.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2495631675","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2495631675","pubTimestamp":1735618395,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cutia Therapeutics (HKG:2487) has completed the phase II clinical trial of CU-20401 for submental adipose accumulation in China, a Tuesday bourse filing said.The clinical trial has shown significant and robust efficacy advantages with a favorable safety profile.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Cutia Therapeutics完成脂肪堆积药物试验，显示安全性和有效性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02487":0.9,"LENZ":1},"content_text":"Cutia Therapeutics (HKG:2487) has completed the phase II clinical trial of CU-20401 for submental adipose accumulation in China, a Tuesday bourse filing said.The clinical trial has shown significant and robust efficacy advantages with a favorable safety profile.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}